First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This prospective, randomized, phase 2 study is conducted to evaluate the efficacy and safety
of first line mCapOX plus cetuximab versus mFOLFOX6 plus cetuximab for metastatic left-sided
CRC patients with wild-type RAS and BRAF genes.
Phase:
Phase 2
Details
Lead Sponsor:
West China Hospital
Collaborator:
First Affiliated Hospital of Chongqing Medical University